{
    "clinical_study": {
        "@rank": "403",
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on April 10, 2020",
            "link_text": "Link to the current ClinicalTrials.gov record.",
            "url": "https://clinicaltrials.gov/show/NCT04315480"
        },
        "id_info": {
            "org_study_id": "TOCICOV-1",
            "nct_id": "NCT04315480"
        },
        "brief_title": "Tocilizumab for SARS-CoV2 Severe Pneumonitis",
        "official_title": "Tocilizumab (RoActemra) as Early Treatment of Patients Affected by SARS-CoV2 Infection With Severe Multifocal Interstitial Pneumonia",
        "sponsors": {
            "lead_sponsor": {
                "agency": "Universit\u00e0 Politecnica delle Marche",
                "agency_class": "Other"
            },
            "collaborator": {
                "agency": "Azienda Ospedaliera Ospedali Riuniti Marche Nord",
                "agency_class": "Other"
            }
        },
        "source": "Universit\u00e0 Politecnica delle Marche",
        "oversight_info": {
            "has_dmc": "No",
            "is_fda_regulated_drug": "No",
            "is_fda_regulated_device": "No",
            "is_us_export": "No"
        },
        "brief_summary": {
            "textblock": "In a Phase 2 Simon's Optimal Two-Stages Design intravenous tocilizumab will be administered\n      as single 8mg/Kg dose in patients affected by severe multifocal interstitial pneumonia\n      correlated to SARS-CoV2 infection. Aim of the study is to test the hypothesis that an\n      anti-IL6 treatment can be effective in calming the virus-induced cytokine storm, blocking\n      deterioration of lung function or even promoting a rapid improvement of clinical conditions,\n      preventing naso-tracheal intubation and/or death."
        },
        "overall_status": "Active, not recruiting",
        "start_date": {
            "@type": "Actual",
            "#text": "March 12, 2020"
        },
        "completion_date": {
            "@type": "Anticipated",
            "#text": "May 2020"
        },
        "primary_completion_date": {
            "@type": "Anticipated",
            "#text": "April 9, 2020"
        },
        "phase": "Phase 2",
        "study_type": "Interventional",
        "has_expanded_access": "No",
        "study_design_info": {
            "intervention_model": "Single Group Assignment",
            "intervention_model_description": "Simon's Two-stages Optimal Design",
            "primary_purpose": "Treatment",
            "masking": "None (Open Label)",
            "masking_description": "Radiologist will be blinded for sequence"
        },
        "primary_outcome": [
            {
                "measure": "arrest in deterioration of pulmonary function",
                "time_frame": "7days",
                "description": "rate of patients with no need in increase of FiO2 to maintain stable SO2 and no need of intubation"
            },
            {
                "measure": "improving in pulmonary function",
                "time_frame": "7 days",
                "description": "rate of patients with change of oxygen saturation >3 percentage points or >10% or decrease in FiO2 need or reduction in pulmonary consolidations >30% at HR CT-scan"
            }
        ],
        "secondary_outcome": [
            {
                "measure": "need of oro-tracheal intubation",
                "time_frame": "+7 days",
                "description": "rate of patients needed of intubation"
            },
            {
                "measure": "death",
                "time_frame": "14days",
                "description": "rate of patients dead"
            }
        ],
        "number_of_arms": "1",
        "enrollment": {
            "@type": "Actual",
            "#text": "38"
        },
        "condition": "SARS Pneumonia",
        "arm_group": {
            "arm_group_label": "tocilizumab",
            "arm_group_type": "Experimental"
        },
        "intervention": {
            "intervention_type": "Drug",
            "intervention_name": "Tocilizumab",
            "description": "single intravenous administration 8mg/Kg",
            "arm_group_label": "tocilizumab"
        },
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  SARS-CoV2 Infection diagnosed by rt-PCR\n\n          -  CT-scan confirmed multifocal interstitial pneumonia\n\n          -  Need of oxygen therapy to maintain SO2>93%\n\n          -  Worsening of lung involvement, defined as (one of the following criteria):\n\n               -  Worsening of oxygen saturation >3 percentage points or decrease in PaO2 >10%,\n                  with stable FiO2 in the last 24h\n\n               -  Need of increase FiO2 in order to maintain a stable SO2 or new onset need of\n                  mechanical ventilation in the last 24h\n\n               -  Increase in number and/or extension of pulmonary areas of consolidation\n\n        Exclusion Criteria:\n\n          -  Age <18 ys and >90 ys\n\n          -  Severe heart failure\n\n          -  Bacterial Infection\n\n          -  Haematological neoplasm\n\n          -  Neutrophil count below 1000/mcl\n\n          -  Platelet count below 50000/mcl\n\n          -  ALT> x5UNL\n\n          -  Inability to give informed consent"
            },
            "gender": "All",
            "minimum_age": "18 Years",
            "maximum_age": "90 Years",
            "healthy_volunteers": "No"
        },
        "location": {
            "facility": {
                "name": "Universit\u00e0 Politecnica delle Marche",
                "address": {
                    "city": "Ancona",
                    "state": "AN",
                    "zip": "60020",
                    "country": "Italy"
                }
            }
        },
        "location_countries": {
            "country": "Italy"
        },
        "reference": [
            {
                "citation": "Tian S, Hu W, Niu L, Liu H, Xu H, Xiao SY. Pulmonary Pathology of Early-Phase 2019 Novel Coronavirus (COVID-19) Pneumonia in Two Patients With Lung Cancer. J Thorac Oncol. 2020 Feb 28. pii: S1556-0864(20)30132-5. doi: 10.1016/j.jtho.2020.02.010. [Epub ahead of print]",
                "PMID": "32114094"
            },
            {
                "citation": "Ashour HM, Elkhatib WF, Rahman MM, Elshabrawy HA. Insights into the Recent 2019 Novel Coronavirus (SARS-CoV-2) in Light of Past Human Coronavirus Outbreaks. Pathogens. 2020 Mar 4;9(3). pii: E186. doi: 10.3390/pathogens9030186. Review.",
                "PMID": "32143502"
            },
            {
                "citation": "Channappanavar R, Perlman S. Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology. Semin Immunopathol. 2017 Jul;39(5):529-539. doi: 10.1007/s00281-017-0629-x. Epub 2017 May 2. Review.",
                "PMID": "28466096"
            },
            {
                "citation": "Zumla A, Ippolito G, Ntoumi F, Seyfert-Margolies V, Nagu TJ, Cirillo D, Chakaya JM, Marais B, Maeurer M. Host-directed therapies and holistic care for tuberculosis. Lancet Respir Med. 2020 Apr;8(4):337-340. doi: 10.1016/S2213-2600(20)30078-3. Epub 2020 Feb 27.",
                "PMID": "32113574"
            }
        ],
        "verification_date": "April 2020",
        "study_first_submitted": "March 14, 2020",
        "study_first_submitted_qc": "March 18, 2020",
        "study_first_posted": {
            "@type": "Actual",
            "#text": "March 19, 2020"
        },
        "last_update_submitted": "April 2, 2020",
        "last_update_submitted_qc": "April 2, 2020",
        "last_update_posted": {
            "@type": "Actual",
            "#text": "April 6, 2020"
        },
        "responsible_party": {
            "responsible_party_type": "Principal Investigator",
            "investigator_affiliation": "Universit\u00e0 Politecnica delle Marche",
            "investigator_full_name": "Armando Gabrielli",
            "investigator_title": "Full Professor Internal Medicine"
        },
        "keyword": "Tocilizumab",
        "condition_browse": {
            "mesh_term": "Pneumonia"
        },
        "patient_data": {
            "sharing_ipd": "No"
        },
        "provided_document_section": {
            "provided_document": {
                "document_type": "Study Protocol",
                "document_has_protocol": "Yes",
                "document_has_icf": "No",
                "document_has_sap": "No",
                "document_date": "March 15, 2020",
                "document_url": "https://ClinicalTrials.gov/ProvidedDocs/80/NCT04315480/Prot_000.pdf"
            }
        }
    }
}